CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro

AIDS

Volumn 18, Issue 16, 2004, Pages 2115-2125

  Vermeire, Kurt ^a   Princen, Katrien ^a   Hatse, Sigrid ^a   De Clercq, Erik ^a   Dey, Kaka ^b   Bell, Thomas W ^b   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

CADA; CD4 receptor; Combination; Downmodulation; Synergy

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ABACAVIR; AMPRENAVIR; ANTIGEN P24; CYCLOTRIAZADISULFONAMIDE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PLANT LECTIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; T LYMPHOCYTE RECEPTOR; TENOFOVIR DISOPROXIL; TRIMERIS; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG STRUCTURE; GALANTHUS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; DRUG SYNERGISM; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 7744237428     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200411050-00003     Document Type: Article

References (65)

1. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:763-767.
2. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, C protein-coupled receptor. Science 1996, 272:872-877.
4. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
5. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998, 93:681-684.
6. Vermeire K, Zhang Y, Princen K, Hatse S, Samala MF, Dey K, et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002, 302:342-353.
7. Vermeire K, Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 2003, 74:667-675.
8. Vermeire K, Bell TW, Choi HJ, Jin Q, Samala MF, Sodoma A, et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharm 2003, 63:203-210.
9. Bell TW, Choi HJ, Harte W, Drew MG. Syntheses, conformations, and basicities of bicyclic triamines. J Am Chem Soc 2003, 125:12196-12210.
10. Skerlj RT, Thornton D, Paclmanabhan S, Martellucci SA, Henson GW, Abrams MJ, et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 1995, 38:366-378.
11. Van Damme EJM, Allen AK, Peumans WJ. Isolation and characterization of a lectin with exclusive specificity towards mannose from snowdrop (Galanthus nivalis) bulbs. FEBS Lett 1987, 215:140-144.
12. Van Damme EJM, Allen AK, Peumans WJ. Related mannose-specific lectins from different species of the family Amaryllidaceae. Plant Physiol 1988, 73:52-57.
13. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Meth 1988, 20:309-321.
14. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
15. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997, 186:1383-1388.
16. Hatse S, Princen K, Bridger C, De Clercq E, Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
17. Balzarini J, Schols D, Neyts J, Van Damme E, Peumans W, De Clercq E. Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother 1991, 35:410-416.
18. Balzarini J, Hatse S, Vermeire K, Princen K, De Clercq E, Van Damme E, et al. Mannose-specific plant lectins may qualify as efficient microbicides against human immunodeficiency virus transmission. HIV DART 2002 Frontiers in Drug Development for Antiretroviral Therapies. Naples, FL, December 2002 [abstract 024].
19. Chesebro B, Buller R, Portis J, Wehrly K. Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol 1990, 64:215-221.
20. Kabat D, Kozak SL, Wehrly K, Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 1994, 68:2570-2577.
21. Kozak SL, Platt EJ, Madani N, Ferro FE, Jr, Peden K, Kabat D. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997, 71:873-882.
22. Platt EJ, Madani N, Kozak SL, Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 1997, 71:883-890.
23. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998, 72:2855-2864.
24. Platt EJ, Kozak SL, Kabat D. Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2000, 16:871-882.
25. Bannert N, Schenten D, Craig S, Sodroski J. The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol 2000, 74:10984-10993.
26. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
27. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
28. Matthews TJ, Wild C, Chen CH, Bolognesi DP, Greenberg ML. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol Rev 1994, 140:93-104.
29. Allaway GP, Ryder AM, Beaudry GA, Maddon PJ. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retroviruses 1993, 9:581-587.
30. Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987, 238:1704-1707.
31. Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988, 331:76-78.
32. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996, 40:234-236.
33. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995, 11:533-539.
34. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003, 77:2859-2865.
35. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990, 112:247-253.
36. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998, 72:4694-4703.
37. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000, 74:326-333.
38. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000, 182:326-329.
39. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004, 189:286-291.
40. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004, 48:423-429.
41. Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. J Infect Dis 2000, 182:1774-1779.
42. Weber J, Nunn A, O'Connor T, Jeffries D, Kitchen V, McCormack S, et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV89.6PD in vitro and in vivo. AIDS 2001, 15:1563-1568.
43. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, et al. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 2003, 17:321-329.
44. Reimann KA, Khunkhun R, Lin W, Gordon W, Fung M. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002, 18:747-755.
45. Poulin L, Evans LA, Tang SB, Barboza A, Legg H, Littman DR, et al. Several CD4 domains can play a role in human immunodeficiency virus infection in cells. J Virol 1991, 65:4893-4901.
46. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, et al. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998, 72:512-519.
47. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, et al. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci USA 1999, 96:6359-6364.
48. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, Mooney LJ, et al. Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 1999, 73:8120-8126.
49. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, Matthews TJ, et al. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 1999, 73:10310-10319.
50. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A. CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 2003, 17:291-300.
51. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J, et al. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J Virol 2001, 75:5230-5239.
52. Kolchinsky P, Kiprilov E, Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001, 75:2041-2050.
53. Martín J, LaBranche CC, González-Scarano F. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J Virol 2001, 75:3568-3580.
54. Vödrös D, Thorstensson R, Doms RW, Fenyö EM, Reeves JD. Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology 2003, 316:17-28.
55. Rusconi S, Merrill DP, La Seta Catamancio S, Citterio P, Bulgheroni E, Croce F, et al. In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs. Antiviral Ther 2000, 5:199-204.
56. Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002, 46:1336-1339.
57. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992, 89:10537-10541.
58. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993, 9:1051-1053.
59. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91:9770-9774.
60. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001, 183:1121-1125.
61. Tremblay CL, Kollmann C, Giguel F, Chou TC, Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000, 25:99-102.
62. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4:1302-1307.
63. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003, 348:2175-2185.
64. Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003, 348:2186-2195.
65. Vermeire K, Hatse S, De Clercq E, Dey K, Samala M, Sodoma A, et al. In vitro synergy between the CD4 down-modulating compound, CADA, and multiple anti-HIV drugs. Antiviral Res 2003, 57:A50.